These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30876846)

  • 1. Walking a tightrope: drug discovery in visceral leishmaniasis.
    Balaña-Fouce R; Pérez Pertejo MY; Domínguez-Asenjo B; Gutiérrez-Corbo C; Reguera RM
    Drug Discov Today; 2019 May; 24(5):1209-1216. PubMed ID: 30876846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visceral leishmaniasis: Revisiting current treatments and approaches for future discoveries.
    No JH
    Acta Trop; 2016 Mar; 155():113-23. PubMed ID: 26748356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening Marine Natural Products for New Drug Leads against Trypanosomatids and Malaria.
    Álvarez-Bardón M; Pérez-Pertejo Y; Ordóñez C; Sepúlveda-Crespo D; Carballeira NM; Tekwani BL; Murugesan S; Martinez-Valladares M; García-Estrada C; Reguera RM; Balaña-Fouce R
    Mar Drugs; 2020 Mar; 18(4):. PubMed ID: 32244488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.
    Annang F; Pérez-Moreno G; García-Hernández R; Cordon-Obras C; Martín J; Tormo JR; Rodríguez L; de Pedro N; Gómez-Pérez V; Valente M; Reyes F; Genilloud O; Vicente F; Castanys S; Ruiz-Pérez LM; Navarro M; Gamarro F; González-Pacanowska D
    J Biomol Screen; 2015 Jan; 20(1):82-91. PubMed ID: 25332350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent patents in the treatment and prevention of leishmaniasis.
    Shahid SK
    Pharm Pat Anal; 2023 Sep; 12(5):237-248. PubMed ID: 38063376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assay development in leishmaniasis drug discovery: a comprehensive review.
    Zulfiqar B; Avery VM
    Expert Opin Drug Discov; 2022 Feb; 17(2):151-166. PubMed ID: 34818139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targets and pathways for the treatment of visceral leishmaniasis.
    Jain V; Jain K
    Drug Discov Today; 2018 Jan; 23(1):161-170. PubMed ID: 28919438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives.
    Alves F; Bilbe G; Blesson S; Goyal V; Monnerat S; Mowbray C; Muthoni Ouattara G; Pécoul B; Rijal S; Rode J; Solomos A; Strub-Wourgaft N; Wasunna M; Wells S; Zijlstra EE; Arana B; Alvar J
    Clin Microbiol Rev; 2018 Oct; 31(4):. PubMed ID: 30158301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy of leishmaniasis: present challenges.
    Uliana SRB; Trinconi CT; Coelho AC
    Parasitology; 2018 Apr; 145(4):464-480. PubMed ID: 28103966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmaniasis chemotherapy--challenges and opportunities.
    Croft SL; Olliaro P
    Clin Microbiol Infect; 2011 Oct; 17(10):1478-83. PubMed ID: 21933306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral miltefosine treatment in children with visceral leishmaniasis: a brief review.
    Palumbo E
    Braz J Infect Dis; 2008 Feb; 12(1):2-4. PubMed ID: 18553005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Replicative In Vitro Assay for Drug Discovery against Leishmania donovani.
    Tegazzini D; Díaz R; Aguilar F; Peña I; Presa JL; Yardley V; Martin JJ; Coteron JM; Croft SL; Cantizani J
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3524-32. PubMed ID: 27021313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a target-free high-throughput screening platform for the discovery of antileishmanial compounds.
    Corman HN; Shoue DA; Norris-Mullins B; Melancon BJ; Morales MA; McDowell MA
    Int J Antimicrob Agents; 2019 Oct; 54(4):496-501. PubMed ID: 31323307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive review of patented antileishmanial agents.
    Rama M; Kumar NV; Balaji S
    Pharm Pat Anal; 2015 Jan; 4(1):37-56. PubMed ID: 25565159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
    Croft SL; Engel J
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapeutic strategies for treatment of visceral leishmaniasis.
    Jain K; Jain NK
    Drug Discov Today; 2013 Dec; 18(23-24):1272-81. PubMed ID: 23973338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery.
    Álvarez-Velilla R; Gutiérrez-Corbo MDC; Punzón C; Pérez-Pertejo MY; Balaña-Fouce R; Fresno M; Reguera RM
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007133. PubMed ID: 30763330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAR refinement of antileishmanial N(2),N(4)-disubstituted quinazoline-2,4-diamines.
    Zhu X; Van Horn KS; Barber MM; Yang S; Wang MZ; Manetsch R; Werbovetz KA
    Bioorg Med Chem; 2015 Aug; 23(16):5182-9. PubMed ID: 25749014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antileishmanial patents antileishmanial current drugs and relevant patents.
    Monzote L
    Recent Pat Antiinfect Drug Discov; 2011 Jan; 6(1):1-26. PubMed ID: 21192776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antileishmanial Drug Development: A Review of Modern Molecular Chemical Tools and Research Strategies.
    Mantravadi PK; Parthasarathy A; Kalesh K
    Curr Med Chem; 2021; 28(31):6337-6357. PubMed ID: 33238841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.